Javascript must be enabled to continue!
MO425: Rosuvastatin Activates Hox13-Usag-1 Pathway and Prevents Renal Fibrosis
View through CrossRef
Abstract
BACKGROUND AND AIMS
Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are primarily cholesterol-lowering drugs that have become standard of care in the primary and secondary prevention of cardiovascular diseases. Apart from lipid-lowering, statins may act beneficially through anti-fibrotic mechanisms to protect the diseased kidney. This study evaluated anti-fibrotic effects of rosuvastatin (RSV) in a chronic kidney fibrosis model and against the TGF-ß1 stimulated Madin-Darby canine kidney (MDCK) cells in vitro.
METHOD
Mice subjected to unilateral ischemic reperfusion injury with contralateral nephrectomy (uIRIx) were treated with vehicle or RSV (10 mg/kg, by oral gavage) daily for 4 weeks and kidneys were analyzed for markers of fibrosis, bone morphogenetic protein-7 (BMP-7), uterine sensitization-associated gene-1 (USAG-1), and SMAD signaling. Control and homeobox protein Hox-A13 (HOXA13) knocked down MDCK cells were stimulated with TGF- ß1 (5 ng/ml) and then treated with RSV.
RESULTS
Kidneys from uIRIx mice showed increased expression of α-SMA, Collagen 1 and decrease in BMP-7 (20.35 ± 2.37 versus 1.00 ± 0.27, P < 0.05; 8.43 ± 1.55 versus 1.00 ± 0.35, P < 0.05; 0.75 ± 0.06 versus 1.00 ± 0.15, P < 0.05, respectively). In contrast, expression of USAG-1, a BMP-7 antagonist, was markedly increased in fibrotic kidney (6.60 ± 1.11 versus 1.00 ± 0.02, P < 0.05). Interestingly, RSV treatment not only attenuated expression of USAG-1 (0.72 ± 0.08 versus 1.36 ± 0.14, P < 0.05) but also showed a tendency to activate expression of HOXA13 (0.36 ± 0.14 versus 0.51 ± 0.15, P > 0.05) and improved other markers of fibrosis. Moreover, RSV treatment significantly reduced phosphorylated Smad3 (3.94 ± 0.81 versus 7.17 ± 1.50, P < 0.05) and increased phosphorylation levels of Smad 1/5/9 (0.67 ± 0.10 versus 0.30 ± 0.09, P < 0.05) that is associated with BMP-7 signaling in the fibrotic kidney. MDCK cells stimulated with TGF-β1 in vitro showed increased expression of α-SMA, fibronectin, vimentin, collagen 1, USAG-1, and phosphorylation of Smad3 as well as decreased expression of phosphorylated Smad 1/5/9. RSV treatment significantly reversed these changes as well as increased level of transcriptional factor HOXA13 (0.89 ± 0.12 versus 0.33 ± 0.08, P < 0.05), which negatively regulates USAG-1, without changes in BMP-7 expression. In addition, effect of RSV treatment on USAG-1 expression was significantly decreased in HOXA13 gene knocked down MDCK cells (1.01 ± 0.19 versus 2.04 ± 0.38, P < 0.05; 1.66 ± 0.13 versus 2.04 ± 0.38, P > 0.05; TGF- ß1 + RSV versus TGF- ß1 and TGF- ß1 + RSV + siRNA vs TGF- ß1, respectively). These in vitro data suggest that RSV enhanced anti-fibrotic pathway by downregulating a dominant BMP-7 antagonist USAG-1 via HOXA13 upregulation and not by enhancing BMP-7 production.
CONCLUSION
The present results demonstrate that RSV inhibits the progression of kidney fibrosis in part by upregulating BMP-7-mediated signaling via HOXA13 expression and down regulation of USAG-1.
Oxford University Press (OUP)
Title: MO425: Rosuvastatin Activates Hox13-Usag-1 Pathway and Prevents Renal Fibrosis
Description:
Abstract
BACKGROUND AND AIMS
Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are primarily cholesterol-lowering drugs that have become standard of care in the primary and secondary prevention of cardiovascular diseases.
Apart from lipid-lowering, statins may act beneficially through anti-fibrotic mechanisms to protect the diseased kidney.
This study evaluated anti-fibrotic effects of rosuvastatin (RSV) in a chronic kidney fibrosis model and against the TGF-ß1 stimulated Madin-Darby canine kidney (MDCK) cells in vitro.
METHOD
Mice subjected to unilateral ischemic reperfusion injury with contralateral nephrectomy (uIRIx) were treated with vehicle or RSV (10 mg/kg, by oral gavage) daily for 4 weeks and kidneys were analyzed for markers of fibrosis, bone morphogenetic protein-7 (BMP-7), uterine sensitization-associated gene-1 (USAG-1), and SMAD signaling.
Control and homeobox protein Hox-A13 (HOXA13) knocked down MDCK cells were stimulated with TGF- ß1 (5 ng/ml) and then treated with RSV.
RESULTS
Kidneys from uIRIx mice showed increased expression of α-SMA, Collagen 1 and decrease in BMP-7 (20.
35 ± 2.
37 versus 1.
00 ± 0.
27, P < 0.
05; 8.
43 ± 1.
55 versus 1.
00 ± 0.
35, P < 0.
05; 0.
75 ± 0.
06 versus 1.
00 ± 0.
15, P < 0.
05, respectively).
In contrast, expression of USAG-1, a BMP-7 antagonist, was markedly increased in fibrotic kidney (6.
60 ± 1.
11 versus 1.
00 ± 0.
02, P < 0.
05).
Interestingly, RSV treatment not only attenuated expression of USAG-1 (0.
72 ± 0.
08 versus 1.
36 ± 0.
14, P < 0.
05) but also showed a tendency to activate expression of HOXA13 (0.
36 ± 0.
14 versus 0.
51 ± 0.
15, P > 0.
05) and improved other markers of fibrosis.
Moreover, RSV treatment significantly reduced phosphorylated Smad3 (3.
94 ± 0.
81 versus 7.
17 ± 1.
50, P < 0.
05) and increased phosphorylation levels of Smad 1/5/9 (0.
67 ± 0.
10 versus 0.
30 ± 0.
09, P < 0.
05) that is associated with BMP-7 signaling in the fibrotic kidney.
MDCK cells stimulated with TGF-β1 in vitro showed increased expression of α-SMA, fibronectin, vimentin, collagen 1, USAG-1, and phosphorylation of Smad3 as well as decreased expression of phosphorylated Smad 1/5/9.
RSV treatment significantly reversed these changes as well as increased level of transcriptional factor HOXA13 (0.
89 ± 0.
12 versus 0.
33 ± 0.
08, P < 0.
05), which negatively regulates USAG-1, without changes in BMP-7 expression.
In addition, effect of RSV treatment on USAG-1 expression was significantly decreased in HOXA13 gene knocked down MDCK cells (1.
01 ± 0.
19 versus 2.
04 ± 0.
38, P < 0.
05; 1.
66 ± 0.
13 versus 2.
04 ± 0.
38, P > 0.
05; TGF- ß1 + RSV versus TGF- ß1 and TGF- ß1 + RSV + siRNA vs TGF- ß1, respectively).
These in vitro data suggest that RSV enhanced anti-fibrotic pathway by downregulating a dominant BMP-7 antagonist USAG-1 via HOXA13 upregulation and not by enhancing BMP-7 production.
CONCLUSION
The present results demonstrate that RSV inhibits the progression of kidney fibrosis in part by upregulating BMP-7-mediated signaling via HOXA13 expression and down regulation of USAG-1.
Related Results
Rosuvastatin Alone or With Extended‐Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia
Rosuvastatin Alone or With Extended‐Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia
Combination therapy with a statin and niacin may provide optimal therapy for patients with combined hyperlipidemia and low levels of highdensity lipoprotein (HDL) cholesterol. The ...
GW24-e0760 Effects of rosuvastatin on rats with dyslipidemia and antiatherosclerotic
GW24-e0760 Effects of rosuvastatin on rats with dyslipidemia and antiatherosclerotic
Objectives
To explore the regulating lipid effects of Rosuvastatin on rats with dyslipidemia and its antiatherosclerotic effects.
...
Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia
Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia
Background: Atorvastatin and rosuvastatin are two widely used HMG-CoA reductase inhibitors (statins). These are used as lipid-lowering drugs to reduce atherosclerosis-induced cardi...
Entanglement of AGE-RAGE axis in cardiac pathosis
Entanglement of AGE-RAGE axis in cardiac pathosis
Abstract
Cardiovascular diseases are the major cause of death globally. Acute coronary syndrome is one of numerous cardiovascular illnesses, including advanced glyc...
THE EFFECTS OF ROSUVASTATIN EFFECT ON THE KIDNEY IN MALE ALBINO RATS
THE EFFECTS OF ROSUVASTATIN EFFECT ON THE KIDNEY IN MALE ALBINO RATS
Background and Aim: Rosuvastatin is known to competitively inhibit HMG-CoA reductase, selectively and reversibly, this enzyme converts HMG-CoA to mevalonic acid in the cholesterol ...
Development of Solid Self – Nanoemulsified Drug Delivery System Containing Rosuvastatin
Development of Solid Self – Nanoemulsified Drug Delivery System Containing Rosuvastatin
This study aims to solidify the self-nanoemulsifying drug delivery system with rosuvastatin (SNEDDS Ros) for application in solid dosage forms. The liquid SNEDDS Ros system is soli...
Relaxant Effect of Rosuvastatin in Isolated Rat Aorta with Perivascular Adipose Tissue
Relaxant Effect of Rosuvastatin in Isolated Rat Aorta with Perivascular Adipose Tissue
Objective: Rosuvastatin displays favorable pleiotropic effects on vascular system to reduce the risk of cardiovascular events besides providing an intensive reduction in LDL-C leve...
Improvement in Endothelium Dysfunction in Diabetics Treated with Statins: A Randomized Comparison of Atorvastatin 20 mg versus Rosuvastatin 10 mg
Improvement in Endothelium Dysfunction in Diabetics Treated with Statins: A Randomized Comparison of Atorvastatin 20 mg versus Rosuvastatin 10 mg
Aim: To investigate the effect a 3‐month treatment with atorvastatin 20 mg compared with rosuvastatin 10 mg on endothelium dysfunction in subjects with diabetes.
Meth...

